Premium
The Management of Advanced Testicular Teratoma
Author(s) -
PECKHAM M.J.,
HORWICH A.,
EASTON D. F.,
HENDRY W. F.
Publication year - 1988
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1988.tb04268.x
Subject(s) - chemotherapy , medicine , germ cell , teratoma , germ cell tumors , oncology , toxicity , surgery , biology , biochemistry , gene
Summary— Of 320 patients with metastatic malignant non‐seminomatous germ cell tumours of the testis (NSGCT) treated with chemotherapy, 266 (83%) are alive and well after a median follow‐up of 39 months. Deaths from treatment‐related causes occurred in 9 patients and were related to intensity of chemotherapy. Relapse after chemotherapy was rare except in presentations with large tumour volume and high serum marker concentrations and a strategy has been developed of risk‐related choice of chemotherapy in order to reduce treatment toxicity in good prognosis sub‐groups of patients.